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Abstract
Background: The plant stanol ester margarine Benecol® is a functional food that has been shown
to lower effectively serum total and LDL-cholesterol. The purpose of this post-marketing study is
to characterize users of plant stanol ester margarine with and without cardiovascular disease.
Methods: A cohort of plant stanol ester margarine users was established based on a compilation
of 15 surveys conducted by the National Public Health Institute in Finland between 1996–2000.
There were 29 772 subjects aged 35–84 years in the cohort. The users of plant stanol ester
margarine were identified by the type of bread spread used.
Results: The plant stanol ester margarine was used as bread spread by 1332 (4.5%) subjects.
Almost half (46%) of the users reported a history of cardiovascular disease. Persons with
cardiovascular disease were more likely to use plant stanol ester margarine (8%) than persons
without cardiovascular disease (3%). Users with and without cardiovascular disease seemed to
share similar characteristics.
In particular, they were elderly people with otherwise healthy life-styles and diet. They were less
likely smokers, more likely physically active and less likely obese than nonusers. The users reported
being in good or average health in general and having used cholesterol-lowering drugs.
Conclusion: Plant stanol ester margarine seems to be used by persons for whom it was designed
and in a way it was meant: as part of efforts for cardiovascular disease risk reduction.
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Introduction
Functional foods are becoming increasingly available to
consumers worldwide. A food can be regarded as "func-
tional" if it has beneficial effects on one or more target
functions in the body, beyond obvious nutritional effects,
that are related to either an improved state of health and
well-being and/or a reduction of disease risk [1]. As the
health effects of long-term use of functional foods are
often unknown, there is a need for post-marketing
research [2-4].
The plant stanol ester margarine Benecol® (Raisio Group,
Raisio, Finland), launched in Finland in 1995, is an exam-
ple of a functional food that has been shown to lower
effectively serum total and LDL-cholesterol levels in sev-
eral interventions [5,6]. Dietary plant sterols, especially
sitostanol, reduce serum cholesterol by inhibiting choles-
terol absorption. The present source of plant sterol is
extraction from a byproduct inthe refining of vegetable
oils or from the oil obtained from pinewoodpulp in
papermaking. A tenth of the amount of plant sterols
found in these plant sterol margarines occurs naturally in
a normal diet. Use of plant sterol ester margarine is recom-
mended, as part of a healthy diet, by the Finnish Society
for Internal Medicine for the primary and secondary pre-
vention of coronary heart disease in Finland [7].
Elevated blood cholesterol is one of the main causal risk
factors for coronary heart disease [8]. Other factors that
affect coronary heart disease include socio-demographic
and life-style characteristics such as age, gender, educa-
tion, region, body-mass index, smoking, physical activity
and diet [9]. As many of these factors relate to life-style,
the risk can be modified to great extent by changes in
health behavior. Indeed, the North Karelia Project in Fin-
land revealed that population rates of cardiovascular dis-
eases can be influenced remarkably by changes in people's
dietary habits [8].
The National Public Health Institute in Finland has mon-
itored health behaviors and chronic disease risk factors in
the Finnish population regularly since 1972. Two survey
systems are especially relevant for the present study: the
Finnish Adult Health Behavior Survey [10] and the
Chronic Disease Risk Factor Survey (Finrisk) [11]. In these
surveys, random samples of the Finnish population are
drawn and risk factors are assessed by a self-administered
questionnaire and direct measurements. Dietary habits,
smoking and physical activity are of special interest in the
monitoring. The surveys conducted in 1996 or later
include a question on plant stanol ester margarine use.
The health effects, both beneficial and adverse, of long-
term use of the plant stanol ester margarine have not been
studied. Therefore, a post-marketing study was started at
the National Public Health Institute in Finland in 1998
[12]. The study includes several sub-studies where existing
survey data as well as health registries in Finland are ana-
lyzed. The data on the adoption of the functional food
during early post-marketing phase is unique and of
importance in relation also to other products of the kind
and to the efficacy of dietary counseling.
Our previous study revealed that users of plant stanol ester
margarine are elderly people (mean age 59 years), about
half of whom have been diagnosed with some form of car-
diovascular disease [12]. The purpose of this study is to
characterize users of plant stanol ester margarine with and
without cardiovascular disease at an early post-marketing
phase. The characteristics of interest are socioeconomic
background, life-style factors, diet and medication. This
information is needed when assessing the efficacy of die-
tary counseling and the possible health effects of the long-
term use of plant stanol ester margarine.
Methods
Fifteen independent health surveys conducted by the
National Public Health Institute in Finland between 1996
and 2000 were combined into study cohort (Table 1 in
Additional File 1). The main surveys were the annual
nationwide Finnish Adult Health Behavior Survey and the
Chronic Disease Risk Factor Survey (Finrisk) carried out in
five areas of Finland. In each survey, sampling was either
entirely random or stratified random with respect to age
and geographical area.
In each survey, the subjects completed mailed question-
naires concerning their health and life-style and returned
them by mail or in person. In the Finrisk Survey, clinical
stage with health examination was included. In the Finrisk
Senior Survey, elderly participants aged 65–74 years, who
were not able to come to the health examination, were
interviewed and examined at their home. The participa-
tion rates in the surveys varied between 64–79%.
The users of plant stanol ester margarine were identified
on the basis of the following question present in each sur-
vey questionnaire: "What type of fat do you usually use on
bread?" Choices were no fat at all, low-fat spread, soft
margarine, butter-oil mixture, butter, and plant stanol
ester margarine Benecol®. The plant stanol ester margarine
Benecol® was the only plant sterol margarine available for
consumers in Finland during the time the health surveys
were conducted.
Subjects who reported myocardial infarction, stroke,
hypertension, heart failure, angina pectoris or intermit-
tent claudication were classified as having cardiovascular
disease. Subjects who did not report any of these condi-
tions were classified as not having cardiovascular disease.Nutrition Journal 2005, 4:20 http://www.nutritionj.com/content/4/1/20
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Overall, 42 692 questionnaires were returned. When
duplicate respondents were identified, only the first
response was retained, thereby reducing the size of the
cohort to 42 406 subjects. Because cardiovascular diseases
and the use of plant stanol ester margarine are infrequent
in younger age groups, we further excluded respondents
aged 15–34 years from the analysis. The final study popu-
lation consisted of 29 772 subjects aged 35–84 years, 14
262 men and 15 510 women.
Unadjusted prevalence percentages among users with and
without cardiovascular disease were computed for age,
sex, socioeconomic background, life-style, body mass
index, self-perceived health, diet and medication. Odds
ratios and 95% confidence limits adjusted for age were
calculated using logistic regression models to compare
users and nonusers of plant stanol ester margarine. Sub-
jects with and without cardiovascular disease were com-
bined in odds ratio calculations. Data management and
statistical analysis were performed using the SAS System
(version 6.12) [13].
Results
Overall, the plant stanol ester margarine was used as the
bread spread of choice by 1332 (4.5%) subjects. Almost
half (46%) of the users and one fourth (25%) of the non-
users reported a history of cardiovascular disease. Table 2
(in Additional File 2)presents the distribution of cardio-
vascular diseases among users and nonusers of plant sta-
nol ester margarine.
Among subjects with cardiovascular disease, the propor-
tion of users of plant stanol ester margarine was 8%,
whereas the proportion among subjects without the dis-
ease was 3% (Table 3 in Additional File 3). In general,
users with and without cardiovascular disease shared sim-
ilar characteristics. The use of plant stanol ester margarine
was most common among subjects aged 65–74 years.
Men were slightly more likely to use plant stanol ester
margarine than women. Urban and married people with
higher levels of education were represented more among
the users than nonusers of plant stanol ester margarine.
Among the users of plant stanol ester margarine, there
were less smokers and more physically active people as
well as less of those with high levels of stress compared
with nonusers (Table 4 in Additional File 4). The users
were also less often obese (defined as body mass index
over 30 kg/m2).
Self-perceived health was good or average among users of
plant stanol ester margarine (Table 5 in Additional File 5).
Users of plant stanol ester margarine consumed higher
amounts of alcohol compared with nonusers. Substan-
tially greater proportion of users also consumed a healthy
diet compared with nonusers.
Users of plant stanol ester margarine used cholesterol-
lowering drugs more commonly than nonusers (Table 6
in Additional File 6). The use of hypertensive drugs, dia-
betic drugs and acetylsalicylic acid for acute myocardial
infarction (AMI) prevention, as well as cardiovascular dis-
ease drugs, were also more common among users than
nonusers of plant stanol ester margarine.
Some continuous variables were evaluated separately for
users with and without cardiovascular disease. The mean
age was 63 years among the users with cardiovascular dis-
ease and 57 years among the users without the disease.
The amounts of plant stanol ester margarine on bread
were almost the same among users with and without car-
diovascular disease: 21 and 20 g per day, respectively.
Blood cholesterol had been measured among 82% and
64%, elevated blood cholesterol had been diagnosed
among 85% and 72%, and dietary counseling for lower-
ing of blood cholesterol had been received by 83% and
71%, of users with and without cardiovascular disease,
respectively. Among nonusers, the respective proportions
were substantially lower. The percentages for blood cho-
lesterol measurement, elevated blood cholesterol, and
dietary counseling were 58% and 28%, 48% and 25%,
and 52% and 31%, for nonusers with and without cardi-
ovascular disease, respectively.
Discussion
The users of plant stanol ester margarine are a self-selected
group of persons who have taken an active interest in their
health. They use plant stanol ester margarine as part of a
generally healthy life-style and diet. Nevertheless, they
commonly have a history of cardiovascular disease or are
at risk to have it. Thus plant stanol ester margarine seems
to be used by persons for whom it was designed and in a
way it was meant: as part of efforts for cardiovascular dis-
ease risk reduction.
Users of plant stanol ester margarine appear in this early
post-marketing adoption phase to be elderly people. They
reported generally good or average health status and took
more commonly cholesterol-lowering drugs as compared
with nonusers. Overall, users with cardiovascular disease
seemed to share similar characteristics compared with
users without cardiovascular disease, although users with
cardiovascular disease tended to be slightly older.
As the plant stanol ester margarine has been recom-
mended in Finland for the primary and secondary preven-
tion of coronary heart disease [7], we assume that the
users with cardiovascular disease attempt to control ele-Nutrition Journal 2005, 4:20 http://www.nutritionj.com/content/4/1/20
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vated cholesterol levels and prevent the progress of the
disease. Users of plant stanol ester margarine who do not
have cardiovascular disease probably also aim to control
cholesterol levels and thus prevent cardiovascular disease.
Unfortunately, we were unable to directly evaluate this
issue, since data on indication for use of plant stanol ester
margarine was not collected.
However, the plant stanol ester margarine users both with
and without cardiovascular disease obviously had more
cholesterol problems than nonusers as they reported
more of elevated blood cholesterol and dietary counseling
for lowering of blood cholesterol. Furthermore, as the
price of the plant stanol ester margarine is 3–5 times
higher than other margarines, its use is likely based on
clearly perceived need, i.e. the control of blood choles-
terol levels.
The use of plant stanol ester margarine may also result
from "practical reasons": if one spouse uses it, the other
may be more likely to use it too. Previous studies show
spouse concordance for physiological and behavioral
indicators such as plasma cholesterol and triglyceride,
blood pressure, diet, body mass index, smoking and phys-
ical exercise [14-17]. The similarity in the characteristics of
plant stanol ester margarine users with and without cardi-
ovascular disease might well be explained by family rea-
sons.
Our information on the use of plant stanol ester marga-
rine was based on a single question concerning the type of
bread spread usually used. Although we have not vali-
dated the question against real use, we assume that the
question reliably measures current use and that conclu-
sions can be drawn concerning the characteristics of the
users. Information concerning the quantity of the plant
stanol ester margarine use was obtained from the Finrisk
survey and was shown to be 20 g per day, on an average.
A picture from a portion size picture booklet describing
the amount of spread on bread was used to improve the
validity of the estimation [18]. The quantity should be
20–25 g per day to achieve an optimal cholesterol-lower-
ing effect [6,7], but it is clear from our data that higher lev-
els of use are common.
The age and geographic distributions of the study cohort
of 42 406 persons differ slightly from the general Finnish
population. The proportion of persons aged 55–64 years
is greater (24% versus 20%) and 65–84 years smaller
(19% versus 24%) than in the general population. The
proportion of persons living in eastern Finland is greater
(20% versus 11%) and southern Finland smaller (30%
versus 40%) compared with the general population. As
the proportion of users is high among less represented
groups, i.e. persons aged 65–74 years and those living in
southern and thus urban areas of Finland, our cohort
probably underestimates the frequency of the use of plant
stanol ester margarine in the Finnish population.
Functional foods are usually carefully examined with
respect to their health effects and safety before they come
to market. These studies often have limitations such as
short length of follow-up. Also effects in certain popula-
tion or patient subgroups might be unknown due to small
sample size. Therefore there is a need for post-marketing
surveillance. Until now only few post-marketing studies
concerning functional foods have been carried out
namely with a food additive sweetener aspartame [19]
and a non-energy fat substitute olestra [20] as the most
notable exceptions.
The LDL-cholesterol reducing effect of plant sterols and
stanols may result in reduced heart disease rates. How-
ever, they appear to somewhat lower lipid-standardized
concentrations of the plasma carotenoids [2,5]. Also the
health effects of high daily amounts of plant sterols and
stanols are unknown. In our future follow-up studies, we
will evaluate possible health effects, both beneficial and
adverse, of the long-term use of the plant stanol ester mar-
garine by linking available Finnish health outcome regis-
tries to the study cohort [12].
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